A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects Under Fed Conditions
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2014
Price : $35 *
At a glance
- Drugs Metformin (Primary) ; Saxagliptin (Primary) ; Saxagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Acronyms SAXA
- Sponsors AstraZeneca
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Jan 2013 New trial record